{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F0ee56071-f8ec-4a4f-9041-588e2cce6bb8","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Chronic Lymphocytic Leukemia \u2014 Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/0ee56071-f8ec-4a4f-9041-588e2cce6bb8\"></iframe>","title":"Chronic Lymphocytic Leukemia \u2014 Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series","description":"\n        <p>Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-na\u00efve and relapsed/refractory chronic lymphocytic leukemia. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/ASHCLL24\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/8f590468-1bb3-4c3c-b0f7-56f239829cc7/cover.jpg"}